328 results on '"Cho, Shih-Feng"'
Search Results
2. Comparison of a novel lateral-flow device to galactomannan assay at different time periods for detections of invasive aspergillosis
3. γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation
4. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models
5. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma
6. A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma
7. Utilizing Advanced Molecular Analysis to Tailor Treatment for Cancer of Unknown Primary Site: A Case Report and Lecture Review.
8. The Prognosis Performance of a Neutrophil- and Lymphocyte-Associated Gene Mutation Score in a Head and Neck Cancer Cohort
9. Investigation of treatment pattern, medical resource utilization and demographic prognostic factors in older patients with non-Hodgkin lymphoma: A nationwide population-based study
10. Patients with head and neck cancer may need more intensive pain management to maintain daily functioning: a multi-center study
11. APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications
12. Serological Responses and Predictive Factors of Booster COVID-19 Vaccines in Patients with Hematologic Malignancies
13. High G9a Expression in DLBCL and Its Inhibition by Niclosamide to Induce Autophagy as a Therapeutic Approach
14. Distinct clinical characteristics of paroxysmal nocturnal hemoglobinuria in patients in Southern Taiwan: A multicenter investigation
15. VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo
16. Supplementary Data from BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression
17. Deciphering the Functions of Telomerase Reverse Transcriptase in Head and Neck Cancer
18. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma
19. Γ-Secretase Inhibitors Enhance the Potency of BCMA-Targeting T Cell Engagers Against Multiple Myeloma Cells without Adverse Impact on T-Cell Activation and Differentiation
20. Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan
21. Bispecific antibodies in multiple myeloma treatment: A journey in progress
22. OAB-009: γ-secretase inhibitors augment efficacy of BCMA-targeting T cell engagers against multiple myeloma cells without impairing T cell effector function
23. Prognostic significance of retention index of bone marrow on dual-phase 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma
24. Tumor and bone marrow uptakes on [18F]fluorodeoxyglucose positron emission tomography/computed tomography predict prognosis in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy
25. Emodin Ameliorates the Efficacy of Carfilzomib in Multiple Myeloma Cells via Apoptosis and Autophagy
26. Revisit of the Association between Cytomegalovirus Infection and Invasive Fungal Infection after Allogeneic Hematopoietic Stem Cell Transplantation: A Real-World Analysis from a High CMV Seroprevalence Area
27. Microenvironment Is a Key Determinant of Immune Checkpoint Inhibitor Response
28. Biomarker potential of nuclear Nrf2 activation in the ABC subtype of diffuse large B‑cell lymphoma.
29. The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan
30. Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma
31. Is it reasonable for the use of Rh‐ee blood? A hospital‐based survey from a southern medical center in Taiwan
32. OAB-021: BCMA-specific ADC MEDI2228 and Daratumumab induce synergistic myeloma cytotoxicity via enhanced IFN-driven innate immune responses and expression of CD38 and NKG2D ligands
33. Effect of Tumor Microenvironment and Angiogenesis on Clinical Outcomes of Primary Central Nervous System Lymphoma
34. Low Geriatric Nutritional Risk Index Is Associated with Poorer Prognosis in Elderly Diffuse Large B-Cell Lymphoma Patients Unfit for Intensive Anthracycline-Containing Therapy: A Real-World Study
35. Progression Risk Score Estimation Based on Immunostaining Data in Oral Cancer Using Unsupervised Hierarchical Clustering Analysis: A Retrospective Study in Taiwan
36. Poor Prognosis of Diffuse Large B-Cell Lymphoma with Hepatitis C Infection
37. BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression
38. COVID-19 Pandemic Is Associated with an Adverse Impact on Burnout and Mood Disorder in Healthcare Professionals
39. Phase I study of ADI‐PEG20 plus low‐dose cytarabine for the treatment of acute myeloid leukemia
40. The Overall Efficacy and Outcomes of Metronomic Tegafur-Uracil Chemotherapy on Locally Advanced Head and Neck Squamous Cell Carcinoma: A Real-World Cohort Experience
41. Isolated central nervous system relapse presenting as myeloid sarcoma of acute myeloid leukemia after allogeneic peripheral blood stem cell transplantation
42. Epidural leukemic involvement and intracranial hemorrhage as initial manifestations in a newly diagnosed chronic myeloid leukemia patient
43. SUV on Dual-Phase FDG PET/CT Correlates With the Ki-67 Proliferation Index in Patients With Newly Diagnosed Non-Hodgkin Lymphoma
44. Primary cardiac lymphoma mimicking atrial thrombus in a patient who underwent permanent pacemaker implantation
45. A tip of the iceberg: Disseminated plasmablastic lymphoma, diagnosed from a local oral lesion
46. A Novel CD138-Targeting Monoclonal Antibody Induces Potent Myeloma Killing and Further Synergizes with IMiDs or Bortezomib in in Vitro and In Vivo Preclinical Models of Human Multiple Myeloma
47. Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice
48. Consistent administration of cetuximab is associated with favorable outcomes in recurrent/metastatic head and neck squamous cell carcinoma in an endemic carcinogen exposure area: a retrospective observational study
49. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma
50. BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.